Tower Research Capital (TRC)’s Pasithea Therapeutics KTTA Stock Holding History
Bought
Maintained
Sold
Other funds holding KTTA
Tower Research Capital (TRC)'s KTTA Position: Q3 2026 in Review
Tower Research Capital (TRC) reduced its Pasithea Therapeutics (KTTA) stake by 30% in Q3 2026, selling an estimated $1.34K and leaving 6,176 shares worth $3.04K. The position accounts for ﹤0.01% of the portfolio, ranked #4975.
Tower Research Capital (TRC) first reported a position in KTTA in Q3 2021 and has held it in 20 quarters since. The position peaked at $52K in Q4 2021. 26 funds tracked by Wall St. Rank hold KTTA as of Q3 2026.
- Tower Research Capital (TRC) held 6,176 shares of Pasithea Therapeutics worth $3.04K as of Q3 2026.
- Tower Research Capital (TRC) sold 2,662 Pasithea Therapeutics shares in Q3 2026, an estimated $1.34K.
- Pasithea Therapeutics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q3 2026, its #4975 holding.
- Tower Research Capital (TRC) first reported a position in Pasithea Therapeutics in Q3 2021 and has held it in 20 quarters since.
- Tower Research Capital (TRC)'s Pasithea Therapeutics position peaked at $52K in Q4 2021.
- 26 funds tracked by Wall St. Rank held Pasithea Therapeutics as of Q3 2026.
Based on Tower Research Capital (TRC)'s 13F filing for Q3 2026, filed 16 Nov 2026.